Both biotechs have been struggling for a while, but there might be some hope for them. The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful. That group includes Novavax (NVAX 6.71%) and Inovio Pharmaceuticals (INO 0.94%). The former did launch a coronavirus vaccine in the U.S., but the latter never got that far. Finally, Novavax has implemented a more disciplined app ...

The vaccine maker's recovery story is looking brighter. Novavax (NVAX 0.81%) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock to a 2,700% gain back in 2020. But when Novavax fell behind on the road to commercialization, the shares declined -- and even the eventual regulatory approval and market entry of that vaccine didn't much help. In recent times, though, Novavax has taken steps t ...

In addition to the above deal, Sanofi also agreed to make an equity investment of nearly $70 million in Novavax in exchange for a 4.9% stake. Shah Capital launched its proxy fight days before the deal with Sanofi was announced, urging investors to vote against three incumbent directors and opposed proposals related to executive compensation at the company's annual meeting on Jun 13. Despite the campaign withdrawal, Shah will continue to monitor the company as it believes that 'significant additional value r ...

Core Viewpoint - The recent price action in speculative stocks indicates a potential resurgence of meme stock enthusiasm, with stocks like Novavax doubling overnight, suggesting a favorable environment for quick profits in cheap speculative stocks [1][2]. Group 1: Speculative Stocks Overview - Speculative stocks carry high risk, and portfolio exposure should be limited to 5% to 10% [2]. - The anticipated rate cuts before the Presidential elections may further support a rally in speculative stocks, encouraging speculation across asset classes [3]. Group 2: Riot Platforms (RIOT) - Riot Platforms has seen sideways movement despite Bitcoin's rise, presenting a good accumulation opportunity with a forward price-earnings ratio of 18.3, and potential for 100% returns [5]. - The company has a cash buffer of $1.3 billion and a zero-debt balance sheet, positioning it for aggressive expansion and significant revenue growth [6]. - Riot's hash rate capacity is expected to increase from 12.4 EH/s in Q1 2024 to 31.5 EH/s by year-end, and further to 40.8 EH/s by mid-2025, with a target of 100 EH/s by 2027 [7]. Group 3: Joby Aviation (JOBY) - Joby Aviation's stock has been subdued, but the upcoming commercialization of its flying car in 2025 presents a strong accumulation opportunity, with potential returns of 3x to 5x in the next 18 months [9][11]. - The company has $924 million in cash and short-term investments, aiming to ramp up production to 500 aircraft per year, which will enhance revenue prospects [12]. Group 4: Plug Power (PLUG) - Plug Power's stock has experienced a 60% correction over the past year, but recent developments suggest a potential reversal [14]. - The company received a conditional loan guarantee of $1.66 billion from the U.S. Department of Energy to develop green hydrogen production facilities, which may boost investor confidence [15]. - Plug Power is also expanding internationally, with a contract for a 3GW electrolyzer plant in Australia and receiving safety certifications in Korea, indicating positive growth prospects [16].

Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Fellow Novavax Stockholders: As a long-term strategic investor, we have been engaging with the board of directors of Novavax (the "Board") for over a year in an attempt to unlock value on behalf of all of its shareholders, so it is heartening that our campaign has begun to deliver positive results. We long advocated for Novavax to explore potential strategic partnership opportunities and believe that the Company's recent announcement ...

The biotech still hasn't lost momentum. Vaccine maker Novavax (NVAX -9.65%) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might sink soon -- Novavax reported positive developments in its latest quarterly update that doubled its share price in just one day. The biotech has come a long way since its not-so-successful attempt at dominating the coronavirus vaccine market. But do more recent developments make Novavax's stock a bu ...

In return, Novavax will get an influx of cash. Sanofi will pay $500 million upfront, and Novavax could get another $700 million depending on development and regulatory milestones. Novavax coulf also receive up to $200 million, plus royalties, "for each additional Sanofi vaccine product developed under a non-exclusive license with Novavax's Matrix-M adjuvant technology." The cash gives Novavax a lot more stability. It has previously raised a "going concern risk" about its business, which means there are doub ...

In fact, consistently beating the S&P 500 — in good times and bad — has been difficult over recent years for individual stocks; for heavyweights in the Health Care sector including LLY, UNH, and JNJ, and even for the megacap stars GOOG, TSLA, and MSFT. In contrast, the Trefis High Quality Portfolio, with a collection of 30 stocks, has outperformed the S&P 500 each year over the same period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less o ...

The first point to note is that Riot ended Q1 2024 with a cash buffer (including Bitcoin (BTC-USD) holdings) of $1.3 billion. Further, with a zero-debt balance sheet, the company has high financial flexibility to pursue aggressive growth. It's also worth noting that the company has set an ambitious target of increasing hash rate capacity from 12.4 EH/s in Q1 2024 to 31.5 EH/s by the end of the year. If Bitcoin remains in an uptrend, this expansion will translate into stellar revenue and EBITDA growth. The m ...

Novavax entered the coronavirus vaccine market late, missing out on the biggest revenue opportunity. This disappointed investors, and the stock plummeted more than 90% from its high. But recent news -- a big partnership with pharmaceutical giant Sanofi -- and Novavax's progress with newer vaccine candidates signal brighter days may be ahead. Could Novavax carve out share in the vaccine market and potentially become the next Moderna? Let's find out. Novavax's $1.2 billion deal Last week, Novavax announced a ...